CHIZF.US China Traditional Chinese Medicine Holdings Co. Limited
- Market cap
- USD 821M
- P/E
- -
- P/B
- 0.28x
- ROE
- -15.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CHIZF.US undervalued?
Graham numberThe Graham number of China Traditional Chinese Medicine Holdings Co. Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
China Traditional Chinese Medicine Holdings Co. Limited fundamental analysis
No fundamental analysis for China Traditional Chinese Medicine Holdings Co. Limited yet.
China Traditional Chinese Medicine Holdings Co. Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About China Traditional Chinese Medicine Holdings Co. Limited
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoc…
Full company profileChina Traditional Chinese Medicine Holdings Co. Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
China Traditional Chinese Medicine Holdings Co. Limited annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.53B | 8.34B | 11.3B | 14.3B | 14.8B | 19.1B | 14.3B | 18.1B | 16.5B | 14.7B | 21.5B |
| Gross Profit | 3.79B | 4.65B | 6.19B | 8.58B | 9.13B | 11.8B | 7.20B | 9.27B | 7.86B | 7.09B | 10.2B |
| Operating Income | 1.44B | 1.79B | 2.16B | 2.46B | 2.49B | 2.75B | 1.06B | 1.43B | 336M | 621M | -723M |
| EBITDA | 1.71B | 2.19B | 2.66B | 3.05B | 3.16B | 3.59B | 2.16B | 2.56B | 1.53B | 1.47B | 1.54B |
| Net Income | 967M | 1.17B | 1.44B | 1.59B | 1.66B | 1.93B | 764M | 1.29B | 54.1M | -342M | -3.06B |
| EPS | 0.22 | 0.26 | 0.30 | 0.32 | 0.33 | 0.38 | 0.15 | 0.26 | 0.01 | -0.07 | -0.61 |
| Balance Sheet | |||||||||||
| Total Assets | 21.0B | 24.9B | 30.3B | 32.5B | 33.1B | 36.4B | 35.6B | 37.1B | 35.1B | 32.4B | 29.9B |
| Total Liabilities | 8.28B | 11.1B | 12.8B | 13.4B | 12.2B | 13.7B | 12.7B | 13.1B | 11.1B | 8.94B | 7.67B |
| Shareholders' Equity | 11.6B | 12.4B | 15.6B | 16.6B | 18.1B | 19.7B | 20.2B | 21.2B | 21.2B | 20.5B | 19.7B |
| Cash & Short-term Investments | 3.20B | 4.53B | 6.04B | 6.80B | 5.03B | 4.14B | 3.46B | 3.69B | 5.34B | 5.16B | 4.57B |
| Total Debt | 3.91B | 5.15B | 6.13B | 5.78B | 5.22B | 5.06B | 5.04B | 5.16B | 4.02B | 2.49B | 1.34B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.46B | 1.24B | 1.19B | 1.59B | 228M | 796M | 1.09B | 1.17B | 2.58B | 2.28B | 2.85B |
| Capital Expenditure | 223M | 628M | 1.26B | 1.17B | 1.25B | 877M | 527M | 489M | 512M | 324M | 427M |
| Free Cash Flow | 1.24B | 608M | -72.2M | 412M | -1.02B | -81.2M | 565M | 680M | 2.07B | 1.96B | 2.43B |
| Ratios | |||||||||||
| ROE | 8.3% | 9.4% | 9.3% | 9.6% | 9.2% | 9.8% | 3.8% | 6.1% | 0.3% | -1.7% | -15.6% |
| ROA | 4.6% | 4.7% | 4.8% | 4.9% | 5.0% | 5.3% | 2.1% | 3.5% | 0.2% | -1.1% | -10.3% |
| Net Profit Margin | 14.8% | 14.0% | 12.8% | 11.1% | 11.2% | 10.1% | 5.3% | 7.1% | 0.3% | -2.3% | -14.3% |
| Debt to Equity | 0.34x | 0.41x | 0.39x | 0.35x | 0.29x | 0.26x | 0.25x | 0.24x | 0.19x | 0.12x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
China Traditional Chinese Medicine Holdings Co. Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 3, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 396M | 0.08 | - |
| 2024 | - | - | - |
| 2023 | CNY 240M | 0.05 | 18.7% |
| 2022 | CNY 314M | 0.06 | 41.1% |
| 2021 | USD 276M | 0.05 | 14.3% |
| 2020 | USD 216M | 0.04 | 13.0% |
| 2019 | USD 502M | 0.10 | 31.6% |
| 2018 | USD 480M | 0.10 | 33.3% |
| 2017 | USD 316M | 0.07 | 27.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns China Traditional Chinese Medicine Holdings Co. Limited
- Insiders 33.46%
- Institutions 17.52%
- Public & others 49.02%
- Shares outstanding 5.04B
- Free float 2.75B
China Traditional Chinese Medicine Holdings Co. Limited company profile
- Company name
- China Traditional Chinese Medicine Holdings Co. Limited
- Ticker
- CHIZF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 13,755
- Fiscal year end
- December
- Address
- Emperor Group Centre, Wan Chai, Hong Kong
- Phone
- 852 2854 3393
- Website
- china-tcm.com.cn
About China Traditional Chinese Medicine Holdings Co. Limited
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM therapies, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical products; investment of the TCM health industry; sale of medical herbs; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong.
China Traditional Chinese Medicine Holdings Co. Limited management
5- Mr. Hongjian LiPresident & Executive Director · born 1987
- Mr. Peng LiExecutive Director · born 1973
- Mr. Jinhong GuoExecutive Chairman · born 1973
- Mr. Lixin ShenVP & Financial Director · born 1967
- Ms. Sau Mei Ng ACIS, ACS, FCIS, FCSCompany Secretary · born 1977